清晨好,您是今天最早来到科研通的研友!由于当前在线用户较少,发布求助请尽量完整地填写文献信息,科研通机器人24小时在线,伴您科研之路漫漫前行!

Locoregional Treatment of Glioblastoma With Targeted α Therapy

医学 多塔 总体生存率 内科学 胶质母细胞瘤 不利影响 肿瘤科 核医学 癌症研究 体内 生物 生物技术
作者
Leszek Królicki,Jolanta Kunikowska,Frank Bruchertseifer,Radosław Kuliński,Dariusz Pawlak,Henryk Koziara,Rafał Rola,Alfred Morgenstern,Adrian Merlo
出处
期刊:Clinical Nuclear Medicine [Lippincott Williams & Wilkins]
卷期号:48 (5): 387-392 被引量:10
标识
DOI:10.1097/rlu.0000000000004608
摘要

Glioblastoma (GB) is the most malignant primary brain tumor. Therefore, introduction of new treatment options is critically important. The aim of this study was to assess local treatment with α emitters [ 213 Bi]Bi-DOTA-substance P (SP) and [ 225 Ac]Ac-DOTA-SP.Treatment was performed as salvage therapy in patients with recurrent primary and secondary GB. [ 213 Bi]Bi-DOTA-SP with injected activity 1.85 GBq per cycle was used in 20 primary (48.2 ± 11.8 years old) and in 9 secondary (38.8 ± 10.8 years old) GB patients and [ 225 Ac]Ac-DOTA-SP in 15 primary (45.1 ± 9.9 years old) and in 6 secondary (37.8 ± 6.4 years old) GB patients with a dose escalation scheme (10, 20, and 30 MBq).Local treatment with [ 213 Bi]Bi-DOTA-SP and [ 225 Ac]Ac-DOTA-SP was well tolerated with only few adverse effects. There was no statistically significant difference between [ 213 Bi]Bi-DOTA-SP and [ 225 Ac]Ac-DOTA-SP groups in survival parameters. For primary GB, survival parameters of patients treated with [ 213 Bi]Bi-DOTA-SP and [ 225 Ac]Ac-DOTA-SP were as follows(in months): progression-free survival time, 2.7 versus 2.4; OS-d (overall survival from time of diagnosis to death from any cause), 23.6 versus 21.0; OS-t (overall survival from the start of treatment to death from any cause), 7.5 versus 5.0; and OS-r (overall survival from recurrence in primary tumors to death from any cause), 10.9 versus 12.0. Survival parameters of secondary GB patients treated with [ 213 Bi]Bi-DOTA-SP and [ 225 Ac]Ac-DOTA-SP were as follows (in months): progression-free survival time, 5.8 versus 2.4; OS-d, 52.3 versus 65.0; OS-t, 16.4 versus 16.0; and OS-c (overall survival from conversion into secondary GB multiforme to death from any cause), 18.4 versus 36.0.The similarity results of 213 Bi or 225 Ac may suggest that the local treatment of brain tumors can be greatly simplified. The experience to date shows that local radioisotope treatment of brain tumors requires further dosimetry studies, taking into account the complexity of biological processes.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
633完成签到 ,获得积分10
11秒前
yuer完成签到 ,获得积分10
12秒前
洁净香寒完成签到,获得积分10
18秒前
叁月二完成签到 ,获得积分10
36秒前
taku完成签到 ,获得积分0
40秒前
41秒前
369ninja发布了新的文献求助10
46秒前
八十七分甜完成签到 ,获得积分10
51秒前
桑稚完成签到 ,获得积分10
51秒前
可爱的函函应助ZXH采纳,获得10
53秒前
naczx完成签到,获得积分0
53秒前
呆萌的孤云完成签到,获得积分10
1分钟前
AAZI完成签到 ,获得积分10
1分钟前
丘比特应助优秀醉易采纳,获得10
1分钟前
Absolute完成签到 ,获得积分10
1分钟前
amm完成签到 ,获得积分10
1分钟前
hnxxangel发布了新的文献求助10
1分钟前
忧心的藏鸟完成签到 ,获得积分10
1分钟前
机灵的夜梅完成签到,获得积分10
1分钟前
lx完成签到 ,获得积分10
1分钟前
singlehzp完成签到 ,获得积分10
2分钟前
偷看星星完成签到 ,获得积分10
2分钟前
搜集达人应助野椒搞科研采纳,获得30
2分钟前
NexusExplorer应助野椒搞科研采纳,获得10
2分钟前
orixero应助野椒搞科研采纳,获得10
2分钟前
秋叶落尘完成签到 ,获得积分10
2分钟前
wwrjj完成签到,获得积分0
2分钟前
和谐寻云完成签到,获得积分10
3分钟前
小二郎完成签到 ,获得积分10
3分钟前
秋雨梧桐完成签到 ,获得积分10
3分钟前
3分钟前
罗山哥发布了新的文献求助10
3分钟前
清脆乘云完成签到,获得积分10
3分钟前
3分钟前
李成恩完成签到 ,获得积分10
4分钟前
4分钟前
4分钟前
4分钟前
4分钟前
4分钟前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
Health Psychology 600
Matrix Methods in Data Mining and Pattern Recognition Second Edition 510
When Is Two-Stage Sample Robust Optimization Asymptotically Optimal? 500
APA handbook of comparative psychology: Basic concepts, methods, neural substrate, and behavior 500
Discerning Saints: Moralization of Intrinsic Motivation and Selective Prosociality at Work 500
Handbuch Trainingswissenschaft – Trainingslehre 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 工程类 有机化学 化学工程 生物化学 计算机科学 内科学 物理 复合材料 催化作用 细胞生物学 无机化学 光电子学 物理化学 电极 基因
热门帖子
关注 科研通微信公众号,转发送积分 7592189
求助须知:如何正确求助?哪些是违规求助? 9169354
关于积分的说明 19626058
捐赠科研通 7170455
什么是DOI,文献DOI怎么找? 3267514
关于科研通互助平台的介绍 2432371
邀请新用户注册赠送积分活动 2259988